Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studySylvie Castaigné, Hervé Dombret, Cécile Pautas et al.|The Lancet|2012Cited by 994
A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic LeukemiaPierre Fenaux, Laurent Degos, Jean‐Jacques Sotto et al.|Blood|1999Cited by 745
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaÉric Jourdan, Hervé Dombret, Nicolas Boissel et al.|Blood|2013Cited by 357
Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trialJuliette Lambert, Sylvie Castaigné, Cécile Pautas et al.|Haematologica|2018Cited by 349
Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort studySylvie Chevret, Élie Azoulay, Peter Pickkers et al.|Intensive Care Medicine|2017Cited by 309